Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKDC11 rituximab plus steroid pulse therapy in childhood-onset refractory steroid-resistant nephrotic syndrome
jRCT2051190019Active, not recruiting
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in nephrosis, sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Primary efficacy endpoint. Started Jun 2019; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on jRCT2051190019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190019.